missing translation for 'onlineSavingsMsg'
Learn More

R&D Systems™ VVD 844

Product Code. 31900363
Change view
Click to view available options
Quantity:
5 mg
Unit Size:
5mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Product Code. Quantity Unit Size
31900363 5 mg 5mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Product Code. 31900363 Supplier R&D Systems™ Supplier No. 8952/5
 Restricted Item
Estimated Shipment: 02-11-2026
Add to basket
Add to basket

missing translation for 'validMainframeMsg'

This item is not returnable. View return policy

A Tocris product, part of R&D Systems. Potent covalent inhibitor of the RAS domain of the PI3K/p110α interaction

VVD 844 is a potent inhibitor of the PI3K/p110α interaction (IC50 = 4 nM) and the phosphorylated-Ser473-AKT (pAKT) pathway (IC50 = 11 nM). It covalently binds cysteine 242 in the RAS domain of PI3K/p110α and blocks RAS activation of PI3Kα activity in vitro.

In vivo, VVD 844 slows growth of RAS mutant tumors and human epidermal growth factor receptor 2 (HER2)-overexpressing tumors, without causing hyperglycemia. Exhibits synergistic effects with Sotorasib (Cat. No. 7713) and Adagrasib (Cat. No. 7488). VVD 844 is orally bioavailable.

TRUSTED_SUSTAINABILITY

Specifications

Chemical Name or Material 5-((1R,2S,5S)-2-(2-Chloro-3-fluorophenyl)-3-azabicyclo[3.1.0]hexan-3-yl)-N-((R,E)-4-(methylsulfonyl)but-3-en-2-yl)pyrazine-2-carboxamide
CAS 3080226-63-4
Quantity 5 mg
Product Line Tocris
Target GTPase Inhibitors
Molecular Formula C21H22ClFN4O3S
Purity 98%
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.